IP Library Granted Patent US 8,927,704
Granted Patent B2
US 8,927,704 · App. 12/303,914 · Granted Jan 6, 2015

Sense oligonucleotide capable of controlling the expression of iNOS and composition comprising the same

Inventors: Tadayoshi Okumura (Hirakata, JP); Mikio Nishizawa (Ibaraki, JP); Yasuo Kamiyama (Takatsuki, JP); Koji Wakame (Sapporo, JP); Takehito Miura (Sapporo, JP)
Assignees: Amino Up Chemical Co., Ltd; Kansai Medical University
C12N15/113C12N2310/11
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,927,704
App. No.
12/303,914
Granted
Jan 6, 2015
Kind
B2
Abstract

The invention relates to sense oligonucleotide having a sequence complementary to a single-stranded RNA (antisense transcript) having a sequence complementary to mRNA of iNOS gene in order to control expression of iNOS (inducible nitric oxide synthase). The sense oligonucleotide of the present invention can control expression of iNOS and is useful for biological defense and treatment and prevention of diseases related to excessive production of NO, such as cancerogenesis, inflammatory disease, endotoxin shock by bacterial infection and the like.

Claims (6)

1. A sense oligonucleotide, wherein said sense oligonucleotide is a synthetic single-stranded DNA oligonucleotide which comprises a sequence complementary to human iNOS (inducible nitric oxide synthase) mRNA antisense transcript, wherein said sequence complementary to human iNOS mRNA antisense transcript is complementary to at least 16 contiguous nucleotides of SEQ ID NO: 11, wherein said sense oligonucleotide is stabilized against decomposition by a nucleolytic enzyme, and wherein the stabilization is performed by a modification selected from the group consisting of LNA, PNA, ENA, and morpholino.

2. The sense oligonucleotide according to claim 1 , wherein said sequence complementary to human iNOS mRNA antisense transcript is complementary to a thermodynamically unstable loop structure in said human iNOS mRNA antisense transcript.

3. The sense oligonucleotide according to claim 1 , wherein said oligonucleotide is 16-335 bases in length.

4. A composition comprising the sense oligonucleotide according to claim 1 , wherein said composition has an activity of suppressing production of NO by promoting decomposition of iNOS mRNA.

5. A method of controlling production of the amount of iNOS, comprising introducing the sense oligonucleotide according to claim 1 into a cell.

6. The sense oligonucleotide of claim 1 , wherein said sense oligonucleotide consists of a nucleotide sequence complementary to a non-stem region in a stem-loop structure of human iNOS (inducible nitric oxide synthase) mRNA antisense transcript.

Assignments (2)
CHANGE OF NAME Recorded Feb 28, 2019
From: AMINO UP CHEMICAL CO., LTD.
To: AMINO UP CO., LTD.
Reel/Frame 050095/0402 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2008
From: OKUMURA, TADAYOSHI; NISHIZAWA, MIKIO; KAMIYAMA, YASUO; WAKAME, KOJI; MIURA, TAKEHITO
To: AMINO UP CHEMICAL CO. LTD.; KANSAI MEDICAL UNIVERISITY
Reel/Frame 021940/0489 →
Priority Claims (1)
JP 2006-159730 · Jun 8, 2006 · national
Continuity (1)
Related Publication 20100248364A1 · Sep 30, 2010